TMCnet News
Malignant Melanoma - Forecast in 20 Major Markets 2016-2026 - Research and MarketsResearch and Markets has announced the addition of the "Malignant Melanoma Forecast in 20 Major Markets 2016-2026" report to their offering. This report provides the current incident population for Malignant Melanoma across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Sweden, Norway, Japan, China, Russia, Australia, Canada, Turkey, South Africa, Saudi Arabia, South Korea, Argentina, Brazil and Mexico) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight, several of the main symptoms and co-morbidities of Malignant Melanoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Main symptoms and co-morbidities for Malignant Melanoma include:
Reasons to Buy:
Key Topics Covered: 1. Introduction 2. Cause of the Disease 3. Risk Factors & Prevention 4. Diagnosis of the Disease 5. Variation by Geography/Ethnicity 6. Disease Prognosis (News - Alert) & Clinical Course 7. Key Co-morbid Conditions associated with the Disease 8. Methodology for Quantification of Patient Numbers 9. Top-Line Malignant Melanoma Incidence 10. Stages and Subtype of Malignant Melanoma 11. Biomarkers and Mutations in Malignant Melanoma 12. Estimates of Treatment Eligible Malignant Melanoma Patients 13. Abbreviations and Acronyms used in the Report 14. Patient-Based Offering 15. Online Pricing Data and Platforms 16. References For more information visit http://www.researchandmarkets.com/research/fgd6ll/malignant View source version on businesswire.com: http://www.businesswire.com/news/home/20160630005489/en/ |